The Wolverine Stack For A CrossFit Shoulder

first, the regulatory part you have to know

BPC-157 and TB-500 are both on the FDA's Category 2 list, which means US compounding pharmacies can't legally make either of them. That's been the rule since 2023. The FDA announced in February 2026 that they intend to move them back to Category 1, but as of this writing, the formal paperwork hasn't published. Until it does, neither peptide is legally prescribable in any form (alone or in combination) through any US telehealth platform or 503A compounding pharmacy. This article isn't a recommendation to use these peptides. It exists because the Wolverine stack gets asked about often enough that an honest read is worth writing.

the lifter who ends up here

You started CrossFit five years ago, or seven, or ten. You got good at it. You moved up in classes. You started doing the more aggressive shoulder-heavy movements: kipping pull-ups, snatches, overhead squats, handstand walks. Somewhere along the way, the right shoulder started talking to you on certain movements. Not pain exactly, but something. You modified, you mobilized, you did the prehab.

Then one day in a metcon (maybe a max-effort snatch, maybe a fatigued thruster, maybe just a routine kipping pull-up at the end of a workout) something gave way. The shoulder hurt. You stopped. You took a week off. You went back gradually. It hasn't been the same since.

That was six months ago, or fourteen months ago. You've done PT. You've done the band exercises and the scap stability work. You've gotten ultrasound and maybe MRI. Maybe you have a labral tear that the orthopedic surgeon wants to operate on. Maybe you have a chronic rotator cuff tendinopathy. Maybe you have impingement with bursitis. Whatever it is, you're functional but not back to where you were. You miss the snatch. You miss feeling strong overhead. And somewhere in your rabbit hole of reading, you found the Wolverine stack (BPC-157 and TB-500, used together) and the forums are full of athletes describing CrossFit shoulder recoveries on it.

Here's what the research actually says about that.

what each peptide is doing, separately

The Wolverine stack is a combination, but understanding what the combination might add requires understanding what each peptide does on its own first.

BPC-157. Body Protection Compound 157. A 15-amino-acid peptide derived from a protein found naturally in gastric juice. Most of the research has been done in rat models, primarily by Predrag Sikiric's group at the University of Zagreb over multiple decades. The repair-effect pattern reported across hundreds of studies covers many tissue types: tendons, ligaments, muscle, gut, vasculature, peripheral nerve. Proposed mechanisms include angiogenesis (new blood vessel growth), nitric oxide pathway modulation, growth hormone receptor interaction, and tight-junction protein effects in epithelial tissue.^[1] We covered the BPC-157 tendon research specifically in BPC-157 and golfer's elbow.

TB-500. A synthetic fragment of Thymosin Beta-4, a small naturally-occurring peptide involved in cell migration during wound healing. The research base is also primarily animal models, with reported effects on soft-tissue healing: tendons, ligaments, muscle, cardiac tissue. Proposed mechanisms include facilitation of cell migration to injury sites, anti-inflammatory effects, and angiogenesis.^[2] We covered the TB-500 research in TB-500 and chronic plantar fasciitis.

Both peptides have plausible mechanisms relevant to soft-tissue injury repair. Both have abundant animal-model data. Both have essentially no controlled human trial data in chronic athletic injuries specifically. Both are on Category 2.

where the wolverine framing came from

The Wolverine stack name traces back to bodybuilding and biohacker culture, referencing the X-Men character's regenerative capability. It started showing up on bodybuilding forums in the early-to-mid 2010s, when both peptides were more freely available through gray-market channels.

The rationale for combining them was mechanistic: BPC-157 and TB-500 appear to act through somewhat different parts of the repair cascade. BPC-157 effects center on tissue-level signaling and angiogenesis; TB-500 effects center on cell migration and inflammation modulation. If both peptides cover different parts of the repair process, combining them might address more of the healing cascade than either alone.

The combination dosing protocols that became standard in forum culture: typically 250-500mcg of BPC-157 once or twice daily, alongside 2-5mg of TB-500 once or twice weekly (TB-500 has a longer half-life and is dosed less frequently). Some protocols inject both subcutaneously near the injury site (local application); others inject systemically. Both protocols have been reported in forum culture with mixed user-reported results.

The critique that has to be made: this combination became standard practice in the biohacker world purely from mechanism reasoning, not from comparative trial data. There has never been a published trial of BPC-157 alone vs. TB-500 alone vs. the combination for any soft-tissue injury indication in humans. The combination might genuinely add to either peptide alone; it might add nothing. The user reports don't resolve this because most users running the protocol are doing one combination, not running a controlled comparison.

what the animal research suggests about combining them

There's some animal-model data on combinations of BPC-157 and TB-500 or BPC-157 and other healing-related peptides, though it's much thinner than the data on each peptide alone.

The rat models that have tested combinations have generally shown effects in the same range as either peptide alone, better than no treatment, but not dramatically better than the single-peptide arm. The pattern is consistent with the partial synergy interpretation rather than the strongly additive interpretation.^[3]

The more useful framing from the animal data: the two peptides probably do cover somewhat different parts of the repair process, and combining them probably adds some incremental effect over either alone. The size of the incremental effect is small relative to the effect of either peptide compared to no treatment. The combination isn't dramatically better than either single peptide; it's modestly better.

The human extrapolation: if both peptides became available again with reclassification, and a clinician was choosing the right approach for a specific patient, the combination is probably the default logic isn't crazy. The combination has the mechanism logic, and the small incremental advantage from covering more of the repair process is probably real. But the difference between just BPC-157 and Wolverine stack may be smaller than the difference between Wolverine stack and adequate PT plus rehab.

the part about crossfit shoulders specifically

Whether the rat tendon research translates to your specific shoulder situation depends partly on what's actually injured.

Rotator cuff tendinopathy. Chronic failed-healing of the rotator cuff tendons (supraspinatus, infraspinatus, subscapularis, teres minor, but mostly supraspinatus). The BPC-157 tendon research is the most directly relevant evidence base. The animal data is consistent with this kind of indication; the human evidence specifically for chronic rotator cuff isn't there.

Labral tear (SLAP or otherwise). Tear in the glenoid labrum, which is the cartilaginous rim of the shoulder socket. This is a different tissue type than tendon, fibrocartilage rather than tendon proper. The BPC-157 research base is thinner for cartilage and labrum specifically. Some mechanism reasoning suggests it might help (the angiogenesis and tissue-repair signaling effects), but the direct evidence is weaker than for tendon.

AC joint issues. Acromioclavicular joint inflammation or arthritis from years of overhead loading. This is joint-related rather than soft-tissue tear-related. The BPC-157 evidence for joint indications is mostly from osteoarthritis models in rodents; the application to human AC joint pathology is mechanistically possible but not specifically validated.

Impingement / bursitis. Mechanical or inflammatory issues in the subacromial space. This is more about mechanical positioning and inflammation than tissue-level damage. The BPC-157 mechanism story doesn't fit this particularly well. The issue isn't a tissue that needs repair, it's a mechanical/inflammatory dynamic that needs space and movement work.

The practical implication: the Wolverine stack mechanism story aligns best with rotator cuff tendinopathy specifically. For other shoulder pathologies, the mechanism reasoning is weaker.

what actually helps a chronic crossfit shoulder

While the peptide stack is in regulatory limbo, the conservative treatment toolkit for chronic CrossFit shoulder is real and accessible.

Adequate rotator cuff and scapular stability work. Most CrossFit shoulders are under-developed in the scapular stabilizers and the smaller rotator cuff muscles relative to the larger prime movers (delts, lats, pecs). The boring stability work that nobody likes (band external rotations, scap retractions, controlled-tempo presses with low weight) is what actually addresses this.

Modification of the movements that broke it. The kipping pull-up, the snatch, the muscle-up, the handstand walk. CrossFit's competitive structure tends to underweight the cost-benefit of high-impingement movements for individuals with already-injured shoulders. A real conversation with a coach about which movements to substitute or eliminate, at least for a period, addresses the underlying loading pattern.

PRP, for the genuine plateau cases. Platelet-rich plasma injection for rotator cuff tendinopathy has mixed evidence but real evidence in the trial literature. For the subset of patients who don't respond to extended PT, this is a reasonable consideration.

Stem cell injection (where legally available). Some clinical settings offer mesenchymal stem cell or BMAC (bone marrow aspirate concentrate) injection for chronic rotator cuff issues. The evidence base is still emerging but there's real research behind it.

Surgical consultation, for structural pathology. For documented labral tears, full-thickness rotator cuff tears, or other structural lesions, surgical consultation is the right next step regardless of what peptides become legal. The peptide conversation isn't a substitute for surgical evaluation of structural injuries.

Rest and load management. The hardest one for CrossFit athletes. The injury that doesn't heal in 3 months of modified training may need 6-9 months of substantially reduced loading. The shoulder won't recover under the loads that injured it, no matter what peptides become available.

the access reality

Both BPC-157 and TB-500 are Category 2. US 503A compounding pharmacies can't make them. The legitimate prescribing channel is closed.

The February 2026 reclassification announcement included both. Formal FDA publication hasn't happened. When it does, the legitimate supply opens back up for both peptides.

For a deeper look at how the regulatory framework around peptide compounding works, see the current state of peptide legality.

The gray-market supply for the Wolverine stack is well-established. The CrossFit community has been particularly active in this market. Many gyms have informal sources or community members who source from research-chemical websites. The standard set of risks applies: unverifiable sourcing, contamination potential, no clinician relationship, no quality control. The fact that other athletes at your gym are using these compounds doesn't make the gray-market sourcing safer for you.

We're not pointing you there. The legitimate version of this conversation, with provider oversight and sterile sourcing, doesn't currently exist in the US. The CrossFit community will run the protocol with or without that legitimate channel. Whether you do is your decision; we just don't have a clean recommendation that involves the gray market.

the summary

The Wolverine stack is real in the sense that the biohacker athletic community has converged on this protocol. The mechanism reasoning is genuine. The animal-model research on both peptides separately is substantial. The combination probably adds some incremental healing effect over either peptide alone, based on the partial-synergy interpretation of the animal data.

The Wolverine stack is also gray-market, currently illegal to prescribe legitimately in the US, and supported by zero published human trials for chronic athletic shoulder pathology specifically.

For a CrossFit athlete with a chronic shoulder issue:

1. Do the boring PT and stability work that addresses the underlying loading pattern that caused the injury. This has real human evidence; it's just not glamorous. 2. Get the structural evaluation (MRI, surgical consultation if indicated) to make sure you're not deferring needed surgery for a peptide protocol that doesn't address structural pathology. 3. Consider PRP if you're in the plateau-after-conservative-treatment situation; the evidence is mixed but real and the intervention is legitimately accessible. 4. Modify the loading pattern. The CrossFit volume that injured you isn't going to heal under that same volume regardless of what peptides become available. 5. Watch for the BPC-157 and TB-500 reclassification. If the legitimate prescribing pathway opens, the conversation about peptide therapy under clinician oversight becomes a real one to have. Until then, the gray-market path carries risks that aren't worth taking for most athletes in this situation.

The Wolverine stack is a real story in athletic peptide culture. It's also not a substitute for the work that actually addresses chronic shoulder issues. Both of those things are true at the same time.